trilaciclib + mFOLFIRINOX

Trilaciclib + mFOLFIRINOX is a combination therapy being investigated for various cancer types, particularly pancreatic cancer. This combination pairs trilaciclib, a CDK4/6 inhibitor designed to reduce chemotherapy-induced myelosuppression, with mFOLFIRINOX, a modified version of the FOLFIRINOX chemotherapy regimen that combines multiple cytotoxic agents. ## Mechanism of Action Trilaciclib works by inducing a reversible G1 cell cycle arrest in hematopoietic stem and progenitor cells, which helps protect them from chemotherapy-induced myelosuppression[7][9]. It specifically inhibits cyclin-dependent kinase 4 (CDK4) at a concentration of 1 nmol/L and cyclin-dependent kinase 6 (CDK6) at 4 nmol/L, causing a temporary pause in the cell cycle for approximately 16 hours[9]. This protective mechanism prevents DNA damage in healthy cells while allowing chemotherapy to target cancer cells effectively. The mFOLFIRINOX component consists of: - Oxaliplatin (85 mg/m²) - Leucovorin (400 mg/m²) - Irinotecan (150 mg/m²) - 5-Fluorouracil (2400 mg/m² over 46 hours)[8][10] ## Clinical Development This combination is currently being investigated in clinical trials for advanced pancreatic cancer. A single-arm, exploratory study is examining trilaciclib combined with mFOLFIRINOX in patients with advanced pancreatic cancer[2]. The study was noted as "not yet recruiting" as of the search results, with a planned enrollment of 30 patients at The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School[1]. While specific results for the trilaciclib + mFOLFIRINOX combination in pancreatic cancer are not yet available, trilaciclib has shown promising results in other cancer types. In a study of trilaciclib with FOLFOXIRI/bevacizumab for metastatic colorectal cancer, trilaciclib significantly reduced the duration of severe neutropenia and other myelosuppressive effects, though it was associated with lower objective response rates and progression-free survival compared to placebo[4]. The canonical name for this drug combination is trilaciclib + mFOLFIRINOX, representing a specific therapeutic approach that combines myeloprotection with a potent multi-agent chemotherapy regimen for the treatment of advanced pancreatic cancer.